Search Results - "Horber, D"

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) by Koeberle, D., Dufour, J.-F., Demeter, G., Li, Q., Ribi, K., Samaras, P., Saletti, P., Roth, A.D., Horber, D., Buehlmann, M., Wagner, A.D., Montemurro, M., Lakatos, G., Feilchenfeldt, J., Peck-Radosavljevic, M., Rauch, D., Tschanz, B., Bodoky, G.

“…Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care for first-line systemic treatment of advanced hepatocellular carcinoma (HCC)…”
Get full text

Choice of first line systemic treatment in pancreatic cancer among national experts by Glatzer, M., Horber, D., Montemurro, M., Winterhalder, R., Inauen, R., Berger, M.D., Pestalozzi, B., Pederiva, S., Pless, M., Putora, P.M.

“…Treatment options for patients with metastatic pancreatic cancer depend on various factors, including performance status, tumor burden and patient preferences…”
Get full text

1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10 by Kienle, D, Winterhalder, R, Koeberle, D, Horber, D, Kueng, M, Saletti, P, Helbling, D, Bastian, S, Dietrich, D, Baertschi, D, Pilop, C, Von Moos, R

Get full text

Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice by RENTSCH, K. M, HORBER, D. H, SCHWENDENER, R. A, WUNDERLI-ALLENSPACH, H, HÄNSELER, E

“…Two liposomal formulations of mitoxantrone (MTO) were compared with the aqueous solution (free MTO) in terms of their pharmacokinetic behaviour in ICR mice and…”
Get full text

Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-β-D-arabinofuranosylcytosine by HORBER, D. H, VON BALLMOOS, P, SCHOTT, H, SCHWENDENER, R. A

“…The clonogenic growth inhibition, the cell cycle dependence of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) cytotoxicity and the capability to induce…”
Get full text

Relevant Upstaging of Pn2 Cm0 Colorectal Cancer Patients with Post-Surgery 18F-Fdg Pet-Ct by Fehr, M., Müller, J., Horber, D., Köberle, D., Cerny, T.T., Gueller, U.

Get full text

573PRELEVANT UPSTAGING OF PN2 CM0 COLORECTAL CANCER PATIENTS WITH POST-SURGERY 18F-FDG PET-CT by Fehr, M., Müller, J., Horber, D., Köberle, D., Cerny, T.T., Gueller, U.

“…Abstract Aim: Data regarding the role of PET-CT in patients with colorectal cancer (CRC) are sparse. Patients with pN2 CRC are at high risk of early relapse…”
Get full text

Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine by HORBER, D. H, SCHOTT, H, SCHWENDENER, R. A

“…The in vitro deamination, cytotoxicity, cellular drug uptake, distribution and cellular pharmacology in HL-60 cells of…”
Get full text

New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens by Schwendener, R A, Gowland, P, Horber, D H, Zahner, R, Schertler, A, Schott, H

“…The antiretroviral activity of two new lipophilic derivatives of azidothymidine (AZT), N4-hexadecyl-2'-deoxyribocytidylyl-(3',5')-3'-azido-2',3'-deoxythy…”
Get more information

Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer by Pestalozzi, B.C., Vass, A., Adam, H., Horber, D.H., Schwendener, R.A., Sauter, Chr

“…Toxicity was evaluable in 22 patients and was mild and predominantly hematological. In 13 patients with weekly documentation, neutropenia was grade 4 in 8 and…”
Get full text

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) super() by Koeberle, D, Dufour, J-F, Demeter, G, Li, Q, Ribi, K, Samaras, P, Saletti, P, Roth, A D, Horber, D, Buehlmann, M, Wagner, A D, Montemurro, M, Lakatos, G, Feilchenfeldt, J, Peck-Radosavljevic, M, Rauch, D, Tschanz, B, Bodoky, G

“…Sorafenib plus everolimus achieved numerically higher response rates in patients with advanced hepatocellular carcinoma (HCC) compared with single-agent…”
Get full text

Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes by Horber, D H, Ottiger, C, Schott, H, Schwendener, R A

“…N4-Hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) is a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine (ara-C) with strong antitumour…”
Get more information

1039PHEALTH ECONOMIC ANALYSIS OF THE RANDOMIZED MULTICENTER PHASE II TRIAL SAKK 77/08: SORAFENIB WITH OR WITHOUT EVEROLIMUS IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) by Matter-Walstra, K., Schwenkglenks, M., Li, Q., Cvijetic, I., Tschanz, B., Samaras, P., Saletti, P., Roth, A.D., Horber, D., Koeberle, D.

“…Abstract Aim: Sorafenib (S), a multitargeted tyrosine kinase inhibitor, has become standard of care for first-line systemic treatment of advanced HCC…”
Get full text

Health Economic Analysis of the Randomized Multicenter Phase Ii Trial Sakk 77/08: Sorafenib with or Without Everolimus in Patients with Unresectable Hepatocellular Carcinoma (Hcc) by Matter-Walstra, K., Schwenkglenks, M., Li, Q., Cvijetic, I., Tschanz, B., Samaras, P., Saletti, P., Roth, A.D., Horber, D., Koeberle, D.

Get full text

Cellular pharmacology of N4-hexadecyl-1-β-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937 by HORBER, D. H, SCHOTT, H, SCHWENDENER, R. A

“…The mechanisms of cytotoxicity, cellular drug uptake, intracellular drug distribution, cellular pharmacokinetics, formation of arabinofuranosylcytosine…”
Get full text

Surgical Prevention of Weight Regain and Type 2 Diabetes Recurrence in 3 Different Bariatric Operations and Their Differential Long-Term Outcome by Rudolf Steffen, MD, Fritz F. Horber, MD

“…Introduction:. Comparative data on long-term outcomes of mechanistically different bariatric operations are scarce. Methods:. In this prospective,…”
Get full text

Cellular pharmacology of a liposomal preparation of N super(4)-hexadecyl-1- beta -D-arabinofuranosylcytosine, a lipophilic derivative of 1- beta -D-arabinofuranosylcytosine by Horber, D H, Schott, H, Schwendener, R A

“…The in vitro deamination, cytotoxicity, cellular drug uptake, distribution and cellular pharmacology in HL-60 cells of N super(4)-hexadecyl-1- beta…”
Get full text

Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne by Horber, D H, Cattaneo-Pangrazzi, R M, von Ballmoos, P, Schott, H, Ludwig, P S, Eriksson, S, Fichtner, I, Schwendener, R A

“…The arabinofuranosylcytosine (AraC) derivative N4-octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC) and its (5'-->5')-heterodinucleoside phosphate analog…”
Get full text

Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations ofN 4-alkyl derivatives of 1-?-d-arabinofuranosylcytosine by Schwendener, R. A., Horber, D. H., Odermatt, B., Schott, H.

Get full text

Oral antitumor activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine by SCHWENDENER, R. A, HORBER, D. H, ODERMATT, B, SCHOTT, H

Get full text